NMOSD and MOGAD Rarely Meet 2024 McDonald Criteria After Red-Flag Screening
KEY TAKEAWAYS
- Systematic screening for MS diagnostic red flags substantially limited the number of patients with NMOSD or MOGAD eligible for assessment under the 2024 McDonald criteria.
- Only 2.3% of patients with NMOSD and 4.8% with MOGAD fulfilled the updated MS diagnostic criteria after red-flag exclusions.
- Findings highlight the continued importance of antibody testing and careful differential diagnosis to minimize MS misclassification.
Systematic evaluation of diagnostic red flags was associated with a low rate of potential multiple sclerosis (MS) misclassification among patients with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), according to findings presented at the 2026 Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026). Although relatively few patients with these MS-mimicking conditions fulfilled the 2024 McDonald diagnostic criteria after red-flag screening, a residual risk of misclassification remained, emphasizing the importance of excluding alternative diagnoses.
The retrospective, multicenter study included 412 patients from 4 Korean referral centers, comprising 266 with aquaporin-4 immunoglobulin G (AQP4-IgG)-positive NMOSD and 146 with MOGAD. Investigators evaluated clinical, MRI, and cerebrospinal fluid (CSF) data collected within 1 year of disease onset. Investigators screened all patients for MS diagnostic red flags before applying the 2024 McDonald criteria. Strong red flags prompted immediate exclusion, and patients with 2 or more intermediate or contextual red flags were also excluded.
What the Diagnostic Data Showed
- Strong red flags: Identified in 201 of 266 patients with NMOSD (76%) and 75 of 146 patients with MOGAD (51%).
- Eligibility after screening: Following additional exclusions for intermediate or contextual red flags, only 6.8% of patients with NMOSD and 18% with MOGAD remained eligible for assessment under the MS criteria.
- Potential MS misclassification: Among the original study populations, 6 patients with NMOSD (2.3%) and 7 with MOGAD (4.8%) ultimately fulfilled the 2024 McDonald criteria despite having an alternative diagnosis.
The findings suggest that systematic consideration of diagnostic red flags can help limit inappropriate application of the updated McDonald criteria in patients with NMOSD or MOGAD. However, the investigators noted that the remaining risk of misclassification was not negligible. They emphasized the importance of antibody testing and comprehensive diagnostic evaluation, particularly in populations where conditions that mimic MS are relatively common.
Source
Kim KH, Kang YR, Choo SH, et al. Low risk of misclassification when applying the 2024 McDonald criteria in NMOSD and MOGAD after red-flag exclusion. Abstract 1467. Presented at: 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026); October 21–23, 2026; Toronto, Ontario, Canada.